Theravance Biopharma, Inc.

and Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, e

. Costs Associated with Exit or Disposal Activities. On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is int

. Regulation FD Disclosure. The information set forth under Item 2.02 of this Current Report is hereby incorporated in Item 7.01 by reference. The information i

. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Theravance Biopharma, Inc., dated March 3, 2026 104 Cover Page Interactive Data File (c